바이오시뮬레이션 시장 : 제공, 용도, 적응증, 최종 사용자,지역별 세계 예측(-2029년)

The biosimulation market is projected to reach USD 9.18 billion by 2029 from USD 4.24 billion in 2024, at a CAGR of 16.7% from 2024 to 2029. Increasing need for cost and time reduction in the drug development process has been one of the major drivers in the adoption of biosimulation tools. These tools predict how the drugs will behave inside the human body, potentially minimizing the requirements of extensive clinical trials. But there are some restraining factors in the market; the cost of biosimulation technologies is discouragingly high and thus, prohibitive to small companies and the academic community.

"Drug Discovery held the largest market share in the biosimulation market in 2023, by application."

The biosimulation market is segmented based on application into drug discovery, drug development, disease modelling, manufacturing & supply chain management and other applications. The drug discovery segment held the largest market share in 2023, since it plays a vital role in accelerating and enriching early stages of pharmaceutical research. The tool created by biosimulation makes it possible for the researchers to simulate drug behavior at the molecular level, predict biological target interaction, even identify potential drug candidates before they reach the costly phases of preclinical and clinical trial stages. It reduces both the time and the cost incurred during the process of drug development.

"By deployment model, the cloud-based model segment is expected to register the fastest growth over the forecast period."

By deployment model, the biosimulation market is divided into on-premises, cloud-based and hybrid model. The cloud-based segment is projected to be the fastest-growing segment over the forecast period. Cloud-based platforms are much more flexible and scalable and make very significant computational resources available at the point when they are needed to run complex biosimulations. This flexibility makes cloud models highly cost-effective, particularly for smaller biotech firms and academic institutions that would lack the infrastructure for high-performance computing.

"Asia Pacific is estimated to register the highest CAGR over the forecast period."

The biosimulation market is geographically segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The Asia Pacific biosimulation market is projected to register highest CAGR during the forecast period. The growth of this region is due to an aggressive build-out of the pharmaceutical and biotechnology industry in this region, especially in China, India, and South Korea, where large investments are committed to drug discovery and development. Markets in this region increasingly embrace sophisticated technology, such as biosimulation, to rationalize their R&D processes, reduce costs, and accelerate their time-to-market for new drugs.

Breakdown of supply-side primary interviews by company type, designation, and region:

• By Company Type: Tier 1 (40%), Tier 2 (35%), and Tier 3 (25%)
• By Designation: Managers (40%), Directors (35%), and Others (25%)
• By Region: North America (40%), Europe (30%), Asia Pacific (20%), Latin America (5%) and Middle East Africa (5%)

List of Companies Profiled in the Report:

• Certara USA. (US)
• Simulations Plus. (US)
• Dassault Systemes (France)
• Schrodinger, Inc. (US)
• Advanced Chemistry Development, Inc. (Canada)
• Chemical Computing Group ULC. (Canada)
• Rosa & Co. LLC. (US)
• Genedata AG (US)
• Physiomics Plc (United Kingdom)
• In Silico Biosciences. (US)
• Allucent. (US)
• OpenEye, Cadence Molecular Sciences. (US)
• Cellworks Group, Inc. (US)
• VeriSIM Life. (US)
• Netabolics SRL (Italy)
• Charnwood Discovery (United Kingdom)
• The MathWorks, Inc. (US)
• ANSYS, Inc (US)
• Instem Group of Companies (United Kingdom)
• Insilico Medicine (US)
• SCM - Software Chemistry & Materials (Netherlands)
• BioSymetrics, Inc. (Canada)
• Atomwise Inc. (US)
• insitro. US)
• Clinithink. (US)

Research Coverage:

This research report categorizes the biosimulation market by offerings (software and services), application (drug discovery, drug development, disease modelling, manufacturing & supply chain and other applications), therapeutic area (oncology, cardiovascular disease, neurological disorders, infectious disease, and others), revenue model (license-based model, subscription-based model, service-based model, and pay-per-use model), deployment model (on-premises model, cloud-based model, and hybrid model) end user (pharmaceutical & biotechnology companies, contract research organizations (CROs), academic & research institutions, regulatory bodies and others), and region. The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the biosimulation market. A thorough analysis of the key industry players has been done to provide insights into their business overview, offerings, and key strategies such as acquisitions, collaborations, partnerships, mergers, product/service launches & enhancements, and approvals in the biosimulation market. Competitive analysis of upcoming startups in the biosimulation market ecosystem is covered in this report.

Reasons to Buy the Report

The report will help market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall biosimulation market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to better position their businesses and plan suitable go-to-market strategies. The report also helps stakeholders understand the market pulse and provides information on key market drivers, restraints, challenges, and opportunities.

The report provides insights on the following pointers:

• Analysis of key drivers: (increase in R&D investments in the pharmaceutical and biotechnology industries), restraints (lack of standardization), opportunities (use of biosimulation solution for pediatric drug development), and challenges (difficulty in matching the complexity of biological systems and processes) influencing the growth of the biosimulation market.
• Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product & service launches in the biosimulation market.
• Market Development: Comprehensive information about lucrative markets - the report analyses the biosimulation market across varied regions.
• Market Diversification: Exhaustive information about new products & services, untapped geographies, recent developments, and investments in the biosimulation market.
• Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players such as Certara USA. (US), Simulations Plus. (US), Dassault Systemes (France), Schrodinger, Inc. (US), Advanced Chemistry Development, Inc. (Canada), Chemical Computing Group ULC. (Canada), Rosa & Co. LLC. (US), Genedata AG (US), etc. among others in biosimulation market. "

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 STUDY SCOPE
  • 1.3.1 MARKETS COVERED & REGIONAL SCOPE
  • 1.3.2 INCLUSIONS & EXCLUSIONS
  • 1.3.3 YEARS CONSIDERED
• 1.4 CURRENCY CONSIDERED
• 1.5 STAKEHOLDERS
• 1.6 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
  • 2.1.1 SECONDARY DATA
    • 2.1.1.1 Key data from secondary sources
  • 2.1.2 PRIMARY DATA
    • 2.1.2.1 Key data from primary sources
    • 2.1.2.2 Insights from primary experts
• 2.2 MARKET SIZE ESTIMATION
• 2.3 DATA TRIANGULATION
• 2.4 MARKET SHARE ESTIMATION
• 2.5 RESEARCH ASSUMPTIONS
• 2.6 LIMITATIONS
  • 2.6.1 METHODOLOGY-RELATED LIMITATIONS
  • 2.6.2 SCOPE-RELATED LIMITATIONS
• 2.7 RISK ASSESSMENT

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 BIOSIMULATION MARKET OVERVIEW
• 4.2 ASIA PACIFIC: BIOSIMULATION MARKET, BY REVENUE MODEL AND COUNTRY (2023)
• 4.3 BIOSIMULATION MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
• 4.4 BIOSIMULATION MARKET: REGIONAL MIX (2024-2029)
• 4.5 BIOSIMULATION MARKET: DEVELOPED VS. EMERGING ECONOMIES

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Increasing R&D investments in pharmaceutical and biotechnology industries
    • 5.2.1.2 Growing adoption of biosimulation software by regulatory bodies
    • 5.2.1.3 Integration of technologically advanced Quantitative Systems Pharmacology (QSP)
    • 5.2.1.4 Need to curtail drug discovery and development costs
    • 5.2.1.5 Growth in biologics and biosimilars markets
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 Lack of standardization
    • 5.2.2.2 Data availability and quality
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Emerging applications
    • 5.2.3.2 Use of biosimulation solutions for pediatric drug development
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Difficulties in matching complexity of biological systems and processes
    • 5.2.4.2 Shortage of biosimulation and modeling experts
• 5.3 ECOSYSTEM ANALYSIS
  • 5.3.1 SOFTWARE PROVIDERS
  • 5.3.2 PHARMACEUTICAL & BIOTECH COMPANIES
  • 5.3.3 CONTRACT RESEARCH ORGANIZATIONS (CROS)
  • 5.3.4 REGULATORY BODIES
  • 5.3.5 ACADEMIC & RESEARCH INSTITUTIONS
• 5.4 CASE STUDY ANALYSIS
  • 5.4.1 CASE STUDY 1: OPTIMIZING ASCIMINIB DEVELOPMENT THROUGH ADVANCED PBPK MODELING
  • 5.4.2 CASE STUDY 2: COMPUTATIONAL DISCOVERY OF SELECTIVE WEE1 INHIBITORS FOR CANCER
  • 5.4.3 CASE STUDY 3: EFFICIENT CLINICAL TRIAL UTILIZING SCALE MANAGEMENT EXPERTISE
• 5.5 VALUE CHAIN ANALYSIS
• 5.6 PORTER'S FIVE FORCES ANALYSIS
  • 5.6.1 BARGAINING POWER OF SUPPLIERS
  • 5.6.2 BARGAINING POWER OF BUYERS
  • 5.6.3 THREAT OF SUBSTITUTES
  • 5.6.4 THREAT OF NEW ENTRANTS
  • 5.6.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.7 REGULATORY ANALYSIS
  • 5.7.1 REGULATORY LANDSCAPE
    • 5.7.1.1 North America
    • 5.7.1.2 Europe
    • 5.7.1.3 Asia Pacific
    • 5.7.1.4 Latin America
    • 5.7.1.5 Middle East & Africa
  • 5.7.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• 5.8 PATENT ANALYSIS
  • 5.8.1 PATENT PUBLICATION TRENDS FOR BIOSIMULATION
  • 5.8.2 JURISDICTION AND TOP APPLICANT ANALYSIS
• 5.9 TECHNOLOGY ANALYSIS
  • 5.9.1 KEY TECHNOLOGIES
    • 5.9.1.1 Mathematical modeling
    • 5.9.1.2 Software platforms
    • 5.9.1.3 Quantitative systems pharmacology (QSP)
  • 5.9.2 COMPLEMENTARY TECHNOLOGIES
    • 5.9.2.1 Data analytics
    • 5.9.2.2 Machine learning and AI
  • 5.9.3 ADJACENT TECHNOLOGIES
    • 5.9.3.1 In silico trials
• 5.10 INDUSTRY TRENDS
  • 5.10.1 DISCOVERY OF BIOMARKERS
  • 5.10.2 ADOPTION IN PERSONALIZED MEDICINE
• 5.11 PRICING ANALYSIS
  • 5.11.1 INDICATIVE PRICING ANALYSIS OF KEY PLAYERS, BY OFFERING, 2023
  • 5.11.2 AVERAGE SELLING PRICE TREND, BY REGION (QUALITATIVE)
• 5.12 KEY CONFERENCES & EVENTS, 2024-2025
• 5.13 KEY STAKEHOLDERS & BUYING CRITERIA
  • 5.13.1 BUYING CRITERIA
• 5.14 TRENDS & DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
• 5.15 END-USER ANALYSIS
  • 5.15.1 UNMET NEEDS
  • 5.15.2 END-USER EXPECTATIONS
• 5.16 INVESTMENT AND FUNDING SCENARIO
• 5.17 IMPACT OF AI/GEN AI ON BIOSIMULATION MARKET
  • 5.17.1 KEY USE CASES
  • 5.17.2 IMPACT OF AI/GEN AI ON INTERCONNECTED AND ADJACENT ECOSYSTEMS
    • 5.17.2.1 Case study
    • 5.17.2.2 Bioinformatics market
    • 5.17.2.3 Drug discovery services market
    • 5.17.2.4 Drug discovery informatics market
  • 5.17.3 USER READINESS & IMPACT ASSESSMENT
    • 5.17.3.1 User readiness
      • 5.17.3.1.1 Pharmaceutical & biotechnology companies
      • 5.17.3.1.2 Contract research organizations
    • 5.17.3.2 Impact assessment
      • 5.17.3.2.1 User A: Pharmaceutical & biotechnology companies
        • 5.17.3.2.1.1 Implementation
        • 5.17.3.2.1.2 Impact
      • 5.17.3.2.2 User B: Academic & research institutes
        • 5.17.3.2.2.1 Implementation
        • 5.17.3.2.2.2 Impact

6 BIOSIMULATION MARKET, BY OFFERING

• 6.1 INTRODUCTION
• 6.2 SOFTWARE
  • 6.2.1 STANDALONE MODULES
    • 6.2.1.1 Molecular modeling & simulation software
      • 6.2.1.1.1 Growing importance of molecular modeling & simulation in drug discovery and development to accelerate market growth
    • 6.2.1.2 PK/PD modeling & simulation software
      • 6.2.1.2.1 Pivotal role in early drug development phase to boost market growth
    • 6.2.1.3 PBPK modeling & simulation software
      • 6.2.1.3.1 Widespread use by regulatory bodies to drive PBPK modeling & simulation software market
    • 6.2.1.4 Toxicity prediction software
      • 6.2.1.4.1 Pressing need for toxicity prediction in drug discovery and development is driving the market
    • 6.2.1.5 Clinical trial simulation software
      • 6.2.1.5.1 High failure rate of clinical trials to accelerate growth
    • 6.2.1.6 Other biosimulation software
  • 6.2.2 INTEGRATED SOFTWARE SUITES/PLATFORMS
    • 6.2.2.1 Need for efficient R&D tools to accelerate growth of integrated platforms
• 6.3 SERVICES
  • 6.3.1 CONSULTING & ADVISORY
    • 6.3.1.1 Need to focus on core competencies to drive need for consulting & advisory services
  • 6.3.2 IMPLEMENTATION, TRAINING, AND SUPPORT
    • 6.3.2.1 Need for well-trained professionals and experts to accelerate market growth
  • 6.3.3 DATA ANALYSIS & INTERPRETATION
    • 6.3.3.1 Accurate and precise interpretation of data to drive need for data analysis & interpretation services

7 BIOSIMULATION MARKET, BY APPLICATION

• 7.1 INTRODUCTION
• 7.2 DRUG DISCOVERY
  • 7.2.1 TARGET IDENTIFICATION & VALIDATION
    • 7.2.1.1 Need for identification of optimal targets in drug discovery to drive market
  • 7.2.2 LEAD IDENTIFICATION & OPTIMIZATION
    • 7.2.2.1 Crucial role in facilitating viable drug discovery to accelerate market growth
• 7.3 DRUG DEVELOPMENT
  • 7.3.1 PRECLINICAL TESTING
    • 7.3.1.1 PK/PD
      • 7.3.1.1.1 Critical role of PK/PD studies in drug development to drive market
    • 7.3.1.2 ADME/Toxicology
      • 7.3.1.2.1 Growing role in selection of potent drug molecules to boost market growth
  • 7.3.2 CLINICAL TRIALS
    • 7.3.2.1 Phase I
      • 7.3.2.1.1 Growing need to ease decision-making process to drive segmental growth
    • 7.3.2.2 Phase II
      • 7.3.2.2.1 Efficiency in dose assessment and product efficacy to drive growth
    • 7.3.2.3 Phase III
      • 7.3.2.3.1 Need to curtail large costs involved in trials to propel demand
    • 7.3.2.4 Phase IV/Post-marketing surveillance
      • 7.3.2.4.1 Ability to assist researchers in process innovation and decision support to drive adoption
• 7.4 DISEASE MODELING
  • 7.4.1 CAPABILITY TO PREDICT DISEASE DYNAMICS AND INFORM THERAPEUTIC STRATEGIES TO DRIVE MARKET GROWTH
• 7.5 MANUFACTURING & SUPPLY CHAIN MANAGEMENT
  • 7.5.1 PRODUCTION PLANNING & OPTIMIZATION
    • 7.5.1.1 Need for proper production planning and execution to drive market growth
  • 7.5.2 QUALITY CONTROL & PROCESS MONITORING
    • 7.5.2.1 Adherence to maintaining product quality to fuel market growth
  • 7.5.3 DEMAND FORECASTING & INVENTORY MANAGEMENT
    • 7.5.3.1 Need to forecast demand effectively to drive market growth
  • 7.5.4 RISK MANAGEMENT & CONTINGENCY PLANNING
    • 7.5.4.1 Need to maintain operational continuity to support market growth
  • 7.5.5 OTHER MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS
• 7.6 OTHER APPLICATIONS

8 BIOSIMULATION MARKET, BY THERAPEUTIC AREA

• 8.1 INTRODUCTION
• 8.2 ONCOLOGY
  • 8.2.1 HIGH PREVALENCE OF CANCER AND SHORTAGE OF EFFECTIVE CANCER DRUGS TO DRIVE MARKET GROWTH
• 8.3 CARDIOVASCULAR DISEASES
  • 8.3.1 RISING NEED FOR DRUGS TO TREAT CARDIOVASCULAR DISEASES TO BOOST MARKET
• 8.4 NEUROLOGICAL DISORDERS
  • 8.4.1 NEED TO BOOST DRUG DISCOVERY AND DEVELOPMENT FOR NEUROLOGICAL DISORDERS TO SUPPORT MARKET GROWTH
• 8.5 INFECTIOUS DISEASES
  • 8.5.1 RISING EPIDEMIC OUTBREAKS TO BOOST DRUG DISCOVERY ACTIVITY
• 8.6 OTHER THERAPEUTIC AREAS

9 BIOSIMULATION MARKET, BY REVENUE MODEL

• 9.1 INTRODUCTION
• 9.2 LICENSE-BASED MODELS
  • 9.2.1 LICENSE-BASED MODELS TO ACCOUNT FOR LARGEST SHARE OF MARKET
• 9.3 SUBSCRIPTION-BASED MODELS
  • 9.3.1 SUBSCRIPTION-BASED MODELS TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD
• 9.4 SERVICE-BASED MODELS
  • 9.4.1 SPECIALIZED SIMULATION EXPERTISE WITH SERVICE-BASED MODELS TO SUPPORT ADOPTION
• 9.5 PAY-PER-USE MODELS
  • 9.5.1 RISING DEMAND FOR FLEXIBLE BIOSIMULATION SOLUTIONS WITHOUT UPFRONT COSTS TO SUPPORT MARKET GROWTH

10 BIOSIMULATION MARKET, BY DEPLOYMENT MODEL

• 10.1 INTRODUCTION
• 10.2 ON-PREMISE MODELS
  • 10.2.1 OPTIMAL CONTROL ON DEPLOYMENT AND DATA BACKUP TO SUPPORT MARKET UPTAKE
• 10.3 CLOUD-BASED MODELS
  • 10.3.1 CLOUD-BASED MODEL TO EXPERIENCE HIGHEST GROWTH RATE DURING FORECAST PERIOD
• 10.4 HYBRID MODELS
  • 10.4.1 BALANCED CAPABILITIES OF HYBRID BIOSIMULATION MODELS TO ACCELERATE ADOPTION

11 BIOSIMULATION MARKET, BY END USER

• 11.1 INTRODUCTION
• 11.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
  • 11.2.1 INCREASING R&D EXPENDITURE FOR DRUG DISCOVERY AND DEVELOPMENT TO DRIVE MARKET
• 11.3 CONTRACT RESEARCH ORGANIZATIONS
  • 11.3.1 RISING OUTSOURCING OF CLINICAL TRIAL ACTIVITIES TO CROS BY PHARMACEUTICAL COMPANIES TO DRIVE MARKET
• 11.4 ACADEMIC & RESEARCH INSTITUTES
  • 11.4.1 FAVORABLE GOVERNMENT SUPPORT FOR RESEARCH TO SUPPORT MARKET GROWTH
• 11.5 REGULATORY BODIES
  • 11.5.1 GROWING USAGE OF BIOSIMULATION SOFTWARE FOR CLINICAL TRIAL EFFICACY TO PROPEL MARKET GROWTH
• 11.6 OTHER END USERS

12 BIOSIMULATION MARKET, BY REGION

• 12.1 INTRODUCTION
• 12.2 NORTH AMERICA
  • 12.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
  • 12.2.2 US
    • 12.2.2.1 Rising government funding for pharmaceutical R&D to drive market
  • 12.2.3 CANADA
    • 12.2.3.1 Increasing funding by Canadian government in healthcare to drive market
• 12.3 EUROPE
  • 12.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
  • 12.3.2 GERMANY
    • 12.3.2.1 High number of sponsored clinical trials to drive uptake of biosimulation
  • 12.3.3 UK
    • 12.3.3.1 Investments by pharmaceutical sponsors for drug discovery services to boost market
  • 12.3.4 FRANCE
    • 12.3.4.1 Growing R&D pipeline for clinical trials to drive market
  • 12.3.5 ITALY
    • 12.3.5.1 Increasing government funds and favorable regulatory scenarios to fuel uptake
  • 12.3.6 SPAIN
    • 12.3.6.1 Established network of research centers to propel market
  • 12.3.7 REST OF EUROPE
• 12.4 ASIA PACIFIC
  • 12.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
  • 12.4.2 CHINA
    • 12.4.2.1 Low cost of drug development and large pharmaceutical R&D base to drive market
  • 12.4.3 INDIA
    • 12.4.3.1 Growing pharmaceutical industry to fuel uptake of biosimulation
  • 12.4.4 JAPAN
    • 12.4.4.1 Established drug development infrastructure and biomedical research capabilities to support market growth
  • 12.4.5 REST OF ASIA PACIFIC
• 12.5 LATIN AMERICA
  • 12.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
  • 12.5.2 BRAZIL
    • 12.5.2.1 Advancing biosimulation in region to support market growth
  • 12.5.3 MEXICO
    • 12.5.3.1 Government initiatives to enhance digital health to propel market growth
  • 12.5.4 REST OF LATIN AMERICA
• 12.6 MIDDLE EAST & AFRICA
  • 12.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
  • 12.6.2 GCC COUNTRIES
    • 12.6.2.1 Increase in healthcare investments to support market growth
  • 12.6.3 REST OF MIDDLE EAST & AFRICA

13 COMPETITIVE LANDSCAPE

• 13.1 INTRODUCTION
• 13.2 KEY PLAYER STRATEGY/RIGHT TO WIN
  • 13.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN BIOSIMULATION MARKET
• 13.3 REVENUE ANALYSIS, 2019-2023
• 13.4 MARKET SHARE ANALYSIS, 2023
• 13.5 RANKING OF KEY MARKET PLAYERS
• 13.6 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
  • 13.6.1 STARS
  • 13.6.2 EMERGING LEADERS
  • 13.6.3 PERVASIVE PLAYERS
  • 13.6.4 PARTICIPANTS
  • 13.6.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
    • 13.6.5.1 Company footprint
    • 13.6.5.2 Offering footprint
    • 13.6.5.3 Application footprint
    • 13.6.5.4 End-user footprint
    • 13.6.5.5 Region footprint
• 13.7 COMPANY EVALUATION MATRIX: START-UP/SMES, 2023
  • 13.7.1 PROGRESSIVE COMPANIES
  • 13.7.2 RESPONSIVE COMPANIES
  • 13.7.3 DYNAMIC COMPANIES
  • 13.7.4 STARTING BLOCKS
  • 13.7.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
• 13.8 COMPANY EVALUATION AND FINANCIAL METRICS, 2025
• 13.9 BRAND/PRODUCT COMPARISON
• 13.10 COMPETITIVE SCENARIO
  • 13.10.1 PRODUCT LAUNCHES & ENHANCEMENTS
  • 13.10.2 DEALS
  • 13.10.3 EXPANSIONS
  • 13.10.4 OTHER DEVELOPMENTS

14 COMPANY PROFILES

• 14.1 KEY PLAYERS
  • 14.1.1 CERTARA, USA
    • 14.1.1.1 Business overview
    • 14.1.1.2 Products & services offered
    • 14.1.1.3 Recent developments
      • 14.1.1.3.1 Product launches & enhancements
      • 14.1.1.3.2 Deals
      • 14.1.1.3.3 Other developments
    • 14.1.1.4 MnM view
      • 14.1.1.4.1 Right to win
      • 14.1.1.4.2 Strategic choices
      • 14.1.1.4.3 Weaknesses & competitive threats
  • 14.1.2 DASSAULT SYSTEMES
    • 14.1.2.1 Business overview
    • 14.1.2.2 Products & services offered
    • 14.1.2.3 Recent developments
      • 14.1.2.3.1 Product launches & enhancements
      • 14.1.2.3.2 Deals
      • 14.1.2.3.3 Other developments
    • 14.1.2.4 MnM view
      • 14.1.2.4.1 Right to win
      • 14.1.2.4.2 Strategic choices
      • 14.1.2.4.3 Weaknesses & competitive threats
  • 14.1.3 SCHRODINGER, INC.
    • 14.1.3.1 Business overview
    • 14.1.3.2 Products & services offered
    • 14.1.3.3 Recent developments
      • 14.1.3.3.1 Deals
      • 14.1.3.3.2 Other developments
    • 14.1.3.4 MnM view
      • 14.1.3.4.1 Right to win
      • 14.1.3.4.2 Strategic choices
      • 14.1.3.4.3 Weaknesses & competitive threats
  • 14.1.4 SIMULATIONS PLUS
    • 14.1.4.1 Business overview
    • 14.1.4.2 Products & services offered
    • 14.1.4.3 Recent Developments
      • 14.1.4.3.1 Product Launches & Enhancements
      • 14.1.4.3.2 Deals
      • 14.1.4.3.3 Other developments
  • 14.1.5 ADVANCED CHEMISTRY DEVELOPMENT, INC.
    • 14.1.5.1 Business overview
    • 14.1.5.2 Products & Services Offered
    • 14.1.5.3 Recent developments
      • 14.1.5.3.1 Product launches & enhancements
      • 14.1.5.3.2 Deals
  • 14.1.6 CHEMICAL COMPUTING GROUP ULC
    • 14.1.6.1 Business overview
    • 14.1.6.2 Products & services offered
    • 14.1.6.3 Recent developments
      • 14.1.6.3.1 Product launches & enhancements
      • 14.1.6.3.2 Deals
      • 14.1.6.3.3 Other developments
  • 14.1.7 ROSA & CO. LLC
    • 14.1.7.1 Business overview
    • 14.1.7.2 Products & services offered
  • 14.1.8 GENEDATA AG (A DANAHER COMPANY)
    • 14.1.8.1 Business overview
    • 14.1.8.2 Products & services offered
    • 14.1.8.3 Recent developments
      • 14.1.8.3.1 Product launches & enhancements
      • 14.1.8.3.2 Deals
  • 14.1.9 PHYSIOMICS PLC
    • 14.1.9.1 Business overview
    • 14.1.9.2 Products & services offered
    • 14.1.9.3 Recent developments
      • 14.1.9.3.1 Product launches & enhancements
      • 14.1.9.3.2 Other developments
  • 14.1.10 IN SILICO BIOSCIENCES
    • 14.1.10.1 Business overview
    • 14.1.10.2 Products & services offered
  • 14.1.11 ALLUCENT
    • 14.1.11.1 Business overview
    • 14.1.11.2 Products & services offered
    • 14.1.11.3 Recent developments
      • 14.1.11.3.1 Deals
      • 14.1.11.3.2 Expansions
      • 14.1.11.3.3 Other developments
  • 14.1.12 OPENEYE, CADENCE MOLECULAR SCIENCES
    • 14.1.12.1 Business overview
    • 14.1.12.2 Products & services offered
    • 14.1.12.3 Recent developments
      • 14.1.12.3.1 Product enhancements
      • 14.1.12.3.2 Deals
      • 14.1.12.3.3 Expansions
  • 14.1.13 CELLWORKS GROUP, INC.
    • 14.1.13.1 Business overview
    • 14.1.13.2 Products & services offered
    • 14.1.13.3 Recent developments
      • 14.1.13.3.1 Other developments
  • 14.1.14 VERISIM LIFE
    • 14.1.14.1 Business overview
    • 14.1.14.2 Products & services offered
    • 14.1.14.3 Recent developments
      • 14.1.14.3.1 Deals
      • 14.1.14.3.2 Other developments
  • 14.1.15 NETABOLICS
    • 14.1.15.1 Business overview
    • 14.1.15.2 Products & services offered
  • 14.1.16 CHARNWOOD DISCOVERY
    • 14.1.16.1 Business overview
    • 14.1.16.2 Products & services offered
    • 14.1.16.3 Recent developments
      • 14.1.16.3.1 Deals
  • 14.1.17 THE MATHWORKS, INC.
    • 14.1.17.1 Business overview
    • 14.1.17.2 Products & services offered
    • 14.1.17.3 Recent developments
      • 14.1.17.3.1 Product enhancements
  • 14.1.18 ANSYS, INC.
    • 14.1.18.1 Business overview
    • 14.1.18.2 Products & services offered
    • 14.1.18.3 Recent developments
      • 14.1.18.3.1 Deals
      • 14.1.18.3.2 Other developments
• 14.2 START-UP/SME PLAYERS
  • 14.2.1 INSTEM GROUP OF COMPANIES
  • 14.2.2 INSILICO MEDICINE
  • 14.2.3 SCM - SOFTWARE CHEMISTRY & MATERIALS
  • 14.2.4 BIOSYMETRICS, INC.
  • 14.2.5 ATOMWISE INC.
  • 14.2.6 INSITRO
  • 14.2.7 CLINITHINK

15 APPENDIX

• 15.1 DISCUSSION GUIDE
• 15.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 15.3 CUSTOMIZATION OPTIONS
• 15.4 RELATED REPORTS
• 15.5 AUTHOR DETAILS